The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study

The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study

Aim: To assess the real-world efficacy of brentuximab vedotin and PD-1 inhibitors versus historical chemotherapy-only salvage regimens in relapsed/refractory classic Hodgkin lymphoma. Methods: Retrospective, single-center study of two cohorts (n=30 each) treated between 1996–2012 (historical) and 2...

Full description

Saved in:
Bibliographic Details
Main Authors: Diana-Marina FORTOES, Elena NICORICI, Cosmin MINCIUNA, Andrei CIANGA, Ramona TIMOFTE, Amalia TITIEANU, Elena DOLACHI-PELIN, Ion ANTOHE, Angela DASCALESCU, Catalin DANAILA
Format: Article
Language:English
Published: Romanian Society of Hematology 2025-06-01
Series:Documenta Haematologica
Subjects:
refractory/relapsed hodgkin lymphoma
brentuximab vedotin
pd-1 inhibitors
autologous stem cell transplant (autosct)
Online Access:https://www.dhrrh.ro/wp-content/uploads/2025/06/DHRRH-2025-2-art2.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dhrrh.ro/wp-content/uploads/2025/06/DHRRH-2025-2-art2.pdf

Similar Items